文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

Osocimab预防膝关节置换术后静脉血栓栓塞的FOXTROT随机临床试验

Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01

FOXTROT试验在54家医院纳入813例单侧膝关节置换患者,比较不同剂量Osocimab与依诺肝素、阿哌沙班的血栓预防效果。术后0.6、1.2、1.8 mg/kg Osocimab相比依诺肝素达到非劣效,术前1.8 mg/kg达到优效;大出血或临床相关非大出血在Osocimab组最高4.7%。

要点

  • 术后Osocimab 0.6、1.2、1.8 mg/kg对比依诺肝素达到非劣效。
  • 术前1.8 mg/kg Osocimab对比依诺肝素达到优效。
  • Osocimab组大出血或临床相关非大出血最高4.7%。

核心结论

  • 膝关节置换患者术后使用Osocimab 0.6、1.2、1.8 mg/kg相比依诺肝素达到非劣效。
  • 术前1.8 mg/kg Osocimab相比依诺肝素达到优效。
  • 需进一步研究确立Osocimab相对于标准血栓预防的疗效与安全性。

研究设计与样本

  • 随机、开放标签、裁定者盲法的2期非劣效试验,在13个国家54家医院开展。
  • 纳入单侧膝关节置换成年患者,2017年10月至2018年8月随机,随访至2019年1月。
  • 813例随机,600例纳入符合方案集用于主要分析。

主要发现

  • 主要终点为术后10至13天静脉血栓栓塞发生率,非劣效界值5%。
  • 术后Osocimab 0.6 mg/kg风险差10.6%(95%CI -1.2%至∞),1.2 mg/kg为9.9%(95%CI -0.9%至∞),1.8 mg/kg为8.4%(95%CI -2.6%至∞)。
  • 术前1.8 mg/kg Osocimab风险差15.1%(双侧90%CI 4.9%至25.2%)。
  • 术后和术前0.3 mg/kg Osocimab未达到非劣效标准,风险差分别为2.6%(95%CI -8.9%至∞)和-3.6%(95%CI -15.5%至∞)。
  • 大出血或临床相关非大出血在Osocimab组最高4.7%,依诺肝素组5.9%,阿哌沙班组2%。

关键数值与推荐

  • 术后Osocimab 0.3 mg/kg组静脉血栓栓塞18例(23.7%),0.6 mg/kg组8例(15.7%),1.2 mg/kg组13例(16.5%),1.8 mg/kg组14例(17.9%)。
  • 术前Osocimab 0.3 mg/kg组23例(29.9%),1.8 mg/kg组9例(11.3%)。
  • 依诺肝素组20例(26.3%),阿哌沙班组12例(14.5%)。
  • 随机人群平均年龄66.5岁(SD 8.2),平均BMI 32.7(SD 5.7),女性74.2%。

临床怎么用

  • 术后Osocimab 0.6、1.2、1.8 mg/kg可作为膝关节置换术后血栓预防的潜在选择。
  • 术前1.8 mg/kg Osocimab显示优于依诺肝素,但需进一步验证。
  • 0.3 mg/kg剂量(术前或术后)未达到非劣效,不宜采用。

局限性

  • 2期试验,样本量有限,主要分析仅600例。
  • 开放标签设计,仅对Osocimab剂量设盲。
  • 需进一步研究确立相对标准预防的疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The efficacy of factor XIa inhibition for thromboprophylaxis is unknown. Osocimab is a long-acting, fully human monoclonal antibody that inhibits factor XIa. OBJECTIVE: To compare different doses of osocimab with enoxaparin and apixaban for thromboprophylaxis in patients who have undergone knee arthroplasty. DESIGN, SETTING, AND PARTICIPANTS: Randomized, open-label, adjudicator-blinded, phase 2 noninferiority trial with observer blinding for osocimab doses, conducted at 54 hospitals in 13 countries. Adult patients undergoing unilateral knee arthroplasty were randomized from October 2017 through August 2018 and followed up until January 2019. INTERVENTIONS: Single intravenous osocimab postoperative doses of 0.3 mg/kg (n = 107), 0.6 mg/kg (n = 65), 1.2 mg/kg (n = 108), or 1.8 mg/kg (n = 106); preoperative doses of 0.3 mg/kg (n = 109) or 1.8 mg/kg (n = 108); or 40 mg of subcutaneous enoxaparin once daily (n = 105) or 2.5 mg of oral apixaban twice daily (n = 105) for at least 10 days or until venography. MAIN OUTCOMES AND MEASURES: The primary outcome was venous thromboembolism incidence between 10 and 13 days postoperatively (assessed by mandatory bilateral venography performed 10 to 13 days after surgery or confirmed symptomatic deep vein thrombosis or pulmonary embolism). A 5% noninferiority margin compared with enoxaparin was chosen. The primary safety outcome of major or clinically relevant nonmajor bleeding was assessed until 10 to 13 days postoperatively. RESULTS: Of 813 randomized participants (mean [SD] age, 66.5 years [8.2 years]; body mass index, 32.7 [5.7]; and 74.2% women), 600 were included in the per-protocol population used for the primary analysis. The primary outcome occurred in 18 patients (23.7%) receiving 0.3 mg/kg, 8 (15.7%) receiving 0.6 mg/kg, 13 (16.5%) receiving 1.2 mg/kg, and 14 (17.9%) receiving 1.8 mg/kg of osocimab postoperatively; 23 (29.9%) receiving 0.3 mg/kg and 9 (11.3%) receiving 1.8 mg/kg of osocimab preoperatively; 20 (26.3%) receiving enoxaparin; and 12 (14.5%) receiving apixaban. Osocimab given postoperatively met criteria for noninferiority compared with enoxaparin with risk differences (1-sided 95% CIs) of 10.6% (95% CI, -1.2% to ∞) at the 0.6-mg/kg dose; 9.9% (95% CI, -0.9% to ∞) at the 1.2-mg/kg dose, and 8.4% (95% CI, -2.6 to ∞) at the 1.8-mg/kg dose. The preoperative dose of 1.8 mg/kg of osocimab met criteria for superiority compared with enoxaparin with a risk difference of 15.1%; 2-sided 90% CI, 4.9% to 25.2%). Postoperative and preoperative doses of 0.3 mg/kg of osocimab did not meet the prespecified criteria for noninferiority, with risk differences (1-sided 95% CIs) of 2.6% (95% CI, -8.9% to ∞) and -3.6% (95% CI, -15.5% to ∞), respectively. Major or clinically relevant nonmajor bleeding was observed in up to 4.7% of those receiving osocimab, 5.9% receiving enoxaparin, and 2% receiving apixaban. CONCLUSIONS AND RELEVANCE: Among patients undergoing knee arthroplasty, postoperative osocimab 0.6 mg/kg, 1.2 mg/kg, and 1.8 mg/kg met criteria for noninferiority compared with enoxaparin, and the preoperative 1.8-mg/kg dose of osocimab met criteria for superiority compared with enoxaparin for the primary outcome of incidence of venous thromboembolism at 10 to 13 days postoperatively. Further studies are needed to establish efficacy and safety of osocimab relative to standard thromboprophylaxis. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03276143.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Weitz JI, Bauersachs R, Becker B, et al. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. JAMA. 2020. PMID: 31935028. doi:10.1001/jama.2019.20687

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。